Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

Osmolality is a well-established parameter for upstream bioprocessing, formulation, analytical development and QC applications throughout the manufacturing of biological drugs. A recent publication ...

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...

- nextBioPharmDSP Horizon 2020 project led by Lek Pharmaceuticals, a Sandoz company in Slovenia, highlighted as success storyfor research and innovation - Completed 18-month milestone submission to EU ...

Real-time and in-line accurate measuring of protein (monoclonal antibody, or mAb) concentration has been shown across a wide dynamic range (0–135 g/L) through the ...